Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: Results of a randomized controlled clinical trial

Table 3 Changes of lymphocytes and NK cells in perioperative period (%, ^-χ±s)

Items Groups		Perioperative period
		A	B	C	D
CD3	Treatment	60.8 ± 6.3	63.0 ± 4.9d	60.3 ± 5.4a	64.2 ± 3.9d
	Control	60.5 ± 4.6	61.0 ± 2.7	56.2 ± 3.8bd	58.6 ± 4.0ab
CD4	Treatment	33.6 ± 4.2	36.3 ± 3.4a	32.8 ± 4.0d	36.6 ± 6.2d
	Control	33.4 ± 3.7	32.8 ± 3.3b	28.1 ± 3.4bd	30.4 ± 3.3ab
CD8	Treatment	30.6 ± 5.2	29.6 ± 4.3	31.1 ± 4.3	29.4 ± 3.6
	Control	31.0 ± 3.9	31.2 ± 4.8	32.9 ± 4.4a	32.1 ± 5.3
CD57+	Treatment	14.8 ± 4.4	15.7 ± 3.8	17.2 ± 3.7	21.1 ± 4.5b
	Control	15.0 ± 2.8	13.1 ± 2.5	14.2 ± 2.2b	15.6 ± 1.7b
CD4	Treatment	1.15 ± 0.34	1.25 ± 0.23a	1.08 ± 0.21d	1.27 ± 0.30d
/CD8	Control	1.11 ± 0.25	1.08 ± 0.22b	0.87 ± 0.17bd	0.98 ± 0.24ab

A: at admission, B: before operation, C: on the 2nd postopera-tive day, D: on the 10th postoperative day.

^aP < 0.05,

^dP < 0.01, B vs A, C vs B, D vs C;

^bP < 0.01 vs treatment group.